For stroke survivors navigating the grueling demands of inpatient rehabilitation, motivation and sustained physical activity are often as limiting as the neurological deficits themselves. An intervention that meaningfully improves both — without pharmacology or expensive equipment — would represent a practical advance for rehabilitation medicine. This randomized controlled trial from Mayo Clinic Proceedings offers evidence that animal-assisted treatment (AAT) may do exactly that.
Fifty hospitalized post-stroke patients were randomly assigned to either standard rehabilitation (occupational, physical, and speech therapy) or the same protocol augmented with structured AAT sessions. Researchers tracked engagement via the Pittsburgh Rehabilitation Participation Scale, physical activity as accelerometry-derived counts per minute, and time spent mobile, alongside physiological markers including salivary cortisol, salivary oxytocin, and cardiac activity. The AAT group demonstrated statistically significant advantages across all three primary behavioral outcomes: rehabilitation participation scores (p=.0038), activity counts per minute (p=.023), and percentage of time mobile (p=.006). Physiological and functional performance data were collected but detailed effect magnitudes were not provided in the excerpt.
This trial is notable for using randomization and objective physiological biomarkers rather than relying solely on self-report, which strengthens its credibility relative to much of the prior animal-assisted intervention literature — a field historically dominated by small, uncontrolled observational studies. The oxytocin and cortisol measurements are particularly interesting: if AAT modulates these stress-reward pathways, it could help explain the engagement effect mechanistically. That said, the sample size of 50 limits statistical power and generalizability, and blinding participants to an animal presence is inherently impossible, introducing performance bias risk. The study also spans a single institution over roughly one year. Whether the engagement gains translate into faster or more complete long-term functional recovery remains an open and clinically critical question. Considered incrementally, this is a well-designed pilot that justifies larger multi-site trials examining functional independence and discharge outcomes as primary endpoints.